This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/02/25

    Tagrisso approved in Japan for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

    AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    01/04/17

    FDA grants full approval for Tagrisso (osimertinib) 80mg for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).- AstraZeneca

    AstraZeneca announced that the FDA has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients...

    Journals
    Journal
    22/11/20

    Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis

    Aim: To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive EGFR mutation.

    • Source: Lung Cancer Management
    Journals
    Journal
    01/01/24

    First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial

    Importance: Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. Objective: To determine the usefulness of osimertinib in previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations.

    • Source: JAMA Oncology
    Journals
    Journal
    09/02/20

    Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Purpose: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations.

    • Source: Journal of Clinical Oncology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/02/24

    Tagrisso (osimertinib) is the first EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting of non-small cell lung cancer

    Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT

    Journals
    Journal
    01/03/24

    Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective

    This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.

    • Source: The Lancet Regional Health - Europe
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    18/02/24

    FDA approves Tagrisso (osimertinib) + chemotherapy to treat metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer .- AstraZeneca

    Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/10/16

    NICE recommends use of Tagrisso (osimertinib) in non-small-cell lung cancer in adults whose disease has progressed only after first-line treatment with an EGFR tyrosine kinase inhibitor- AstraZeneca

    Tagrisso (osimertinib), from AstraZeneca, is recommended by the UK NICE (National Institute for Health and Care Excellence)as an option for...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/05/25

    Tagrisso (osimertinib) recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA Phase III trial, which were published in The New England Journal of Medicine

    See more